Prof. Ritu Raman has developed centimeter-scale robots that use biological muscle, reports Liam Drew for Nature. “Raman is now developing muscle systems connected to neurons that can trigger contraction, just as they exist in animals,” writes Drew. “In the longer term, she aims to use networks of biological neurons that can sense external stimuli as well, enabling them to move in response to environmental cues.”
Boston Globe reporter Robert Weisman spotlights Integrated Biosciences, a startup co-founded by MIT researchers that is using artificial intelligence to identify anti-aging drug candidates. “We’re trying to go after aging and aging-associated disorders,” says postdoc Felix Wong. “We all know loved ones who have suffered from some of these conditions.”
Ginkgo Bioworks, a biotech company founded by Jason Kelly BS ’03, PhD ’08, Reshma Shetty PhD ‘08, Barry Canton PhD ’08, Austin Che PhD ’08 and Professor Tom Knight, is working to develop synthetic fragrances, reports Scott Kirsner for The Boston Globe.
Prof. Ritu Raman speaks with Scientific American about her work “building machines that we call bio-hybrid because they're part biological and part made out of synthetic materials. The biological robots that we're building are powered by muscle tissue so that every time the muscle contracts, you could get something that looks like movement.”
Asimov - an MIT spinout co-founded by Prof. Christopher Voigt, Alec Nielsen PhD ’16, Raja Srinivas PhD ’16, and Boston University Prof. Douglas Densmore - is a biotechnology company developing tools to design living systems, reports John Cumbers for Forbes. “Every cell is capable of computing. Perceiving environmental signals, information processing, turning genes on and off,” says Nielsen. “The ability to engineer this gift of evolution is, in my view, going to be the most meaningful and impactful technology that humans have ever developed.”
Scientists from MIT, Georgia Institute of Technology, Sun Yat-sen University and Beijing-based AI startup Galixir have developed a deep-learning toolkit that can predict biosynthetic pathways for natural products, which are a primary source of clinical drug discovery, reports Xinhua Net. “The researchers presented a toolkit called Bionavi-NP to propose NP biosynthetic pathways from simple building blocks in an oprtimal fashion, which requires no already-known biochemical rules,” writes Xinhua Net.
MIT startup Volta Labs is developing a new instrument that can automate the processes used to prepare genetic samples, reports Emma Betuel for TechCrunch. CEO and co-founder Udayan Umapathi ’17 is confident that with the right programming, the platform could allow “liquids to be manipulated in even more complex ways, like using magnetic fields to draw certain molecules out of samples for further analysis,” writes Betuel.
Researchers from MIT and the Smithsonian Conservation Biology Institute are developing a probiotic to cure amphibian chytrid fungus in frogs, reports Jennifer Zoon for Smithsonian Magazine.
New York Times reporter Steve Lohr spotlights the origin and history of MIT startup Gingko Bioworks, a synthetic biology company founded with a “shared belief that biology could be made more like computing with reusable code and standard tools instead of the bespoke experiments of traditional biology." Jason Kelly ’03, PhD ’08, one of the founders of MIT startup Ginkgo Bioworks and the company’s chief executive, explains that “the ultimate goal for Ginkgo is to make it as easy to program a cell as it is to program a computer.”
Ginkgo Bioworks founders Jason Kelly PhD ’08, S.B. ’03 and Reshma Shetty PhD ’08 speak with Boston Globe reporter Scott Kirsner about the inspiration for and growth of the company, which is focused on manipulating genetic material to get living cells to perform new jobs. Shetty notes that the Ginkgo Bioworks team is “dedicated to making biology easier to engineer."
New Scientist reporter Layal Liverpool writes that a new study co-authored by MIT researchers finds that “synthetic cells made by combining components of Mycoplasma bacteria with a chemically synthesised genome can grow and divide into cells of uniform shape and size, just like most natural bacterial cells.”
Prof. Kristala L. J. Prather speaks with Korie Grayson of C&EN about her career path and her work harnessing the synthetic power of microbial systems. Of the importance of mentorship, Prather notes, “The exponential way in which you can actually have a positive impact is by taking good care of the people who are placed into your academic and intellectual trust. That’s how we make a difference.”
Prof. James Collins speaks with Molly Wood of Marketplace about his work developing a faster, cheaper and more accurate Covid-19 diagnostic. Collins explains that his research group is “using synthetic biology to create highly sensitive, low-cost diagnostics, some that are now approved for use in clinical diagnostics labs, and now we’re moving towards point-of-care diagnostics, as well as at-home diagnostics.”
Forbes reporter Amy Feldman spotlights MIT startup Ginkgo Bioworks, which aims to “design, modify and manufacture organisms to make existing industrial processes cheaper and entirely new processes possible.” Feldman notes that the promise of synthetic biology is “not just a proliferation of new products, but also a reduction of the environmental harm that comes from our heavy reliance on petrochemicals.”
Guardian reporter Ian Sample writes that MIT startup Synlogic are developing a “living” medicine” made from genetically modified bugs. “By engineering these bacteria, we are able to control how they operate in the human gastrointestinal tract,” says Caroline Kurtz of Synlogic. “It allows us to think about many other diseases where you may need to produce something beneficial, or remove something that is toxic for the patient.”